Tamoxifen-Resistant MCF7 Breast Cancer Cells (MCF7/TAMR-4)
Payment Options
We accept Visa and MasterCard in our online store.
Worldwide Shipping
We can get your purchases to you wherever you are.
Customer Care
As an Axol customer you have access to our support team and product specialists.
Description
MCF7/TAMR-4 and MCF7/TAMR-8 are tamoxifen-resistant MCF7 breast cancer cell lines. The parental MCF7/S0.5 line was treated with 1 μM tamoxifen for 28 days which killed the majority of the cells. The surviving cells were clonally expanded as sublines in the absence of tamoxifen for 19 passages and were then treated continuously with 1 μM tamoxifen. The resistant cells continued to proliferate and approached a growth rate that was comparable to the parental MCF7/S0.5 line.
Condition of sale: the end user is not permitted to transfer or re-freeze the cells.
Product Specification
| Donor gender | Female |
| Donor age at sampling | 69 yrs |
| Genetic modification | None |
| Size | 1 million cells |
| Growth properties | Adherent |
| Disease information | Malignant adenocarcinoma derived from pleural effusion |
| General notes | Expresses the estrogen receptor (ER); resistant to tamoxifen at 1 μM |
| Shipping conditions | Dry ice |
| Storage conditions | vapour phase nitrogen |
| Usage notes | Culture in DMEM/F12 medium (no phenol red) supplemented with 1% fetal bovine serum + 2.5 mM GlutaMAX + 6 ng/mL insulin. Addition of 1 μM tamoxifen is required to maintain a high level of resistance |
| Condition of sale | The end user is not permitted to transfer or re-freeze the cells |
Technical Resources
References
- Sarwar N, Kim JS, Jiang J et al. Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocrine-related Cancer (2006)
- Cutrupi S, Reineri S, Panetto A et al. Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells. Oncogene (2012)
- Pancholi S, Lykkesfeldt AE, Hilmi C et al. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocrine-related Cancer (2008)
- Millour J, Constantinidou D, Stavropoulou AV et al. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene (2010)
- Elias D, Vever H, Lænkholm AV et al. Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene (2015)
- Joshi T, Elias D, Stenvang J et al. Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer. Oncotarget (2016)
- Thrane S, Lykkesfeldt AE, Larsen MS et al. Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Research and Treatment (2013)
- Larsen MS, Yde CW, Christensen IJ et al. Carboplatin treatment of antiestrogen-resistant breast cancer cells. International Journal of Oncology (2012)
- Pedersen AM, Thrane S, Lykkesfeldt AE et al. Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α. International Journal of Oncology (2014)
- Thrane S, Pedersen AM, Thomsen MB et al. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells. Oncogene (2015)